文献速递血栓与止血

胎儿/新生儿同种免疫性血小板减少症:HLA-DRB3*01:01对胎儿/新生儿结局影响的系统综述

Fetal/neonatal alloimmune thrombocytopenia: a systematic review of impact of HLA-DRB3*01:01 on fetal/neonatal outcome.
PubMed 文献 · Blood Adv · 2020-01-01

该系统综述与荟萃分析纳入4项前瞻性研究和8项回顾性研究,评估母亲HLA-DRB3*01:01与HPA-1a同种免疫及新生儿结局的关联。前瞻性研究人群超过150 000,64例严重血小板减少新生儿母亲均为HLA-DRB3*01:01阳性;HLA-DRB3*01:01阴性母亲同种免疫的OR为0.05(95%CI 0.00-0.60),严重新生儿血小板减少的OR为0.08(95%CI 0.02-0.37)。

要点

  • 前瞻性研究中64例严重血小板减少新生儿(血小板计数<50×10⁹/L)的母亲均为HLA-DRB3*01:01阳性。
  • 回顾性研究中214例严重血小板减少患儿有205例出生于HLA-DRB3*01:01阳性母亲。
  • HLA-DRB3*01:01阴性母亲同种免疫OR为0.05(95%CI 0.00-0.60),严重新生儿血小板减少OR为0.08(95%CI 0.02-0.37)。

核心结论

  • 对于HPA-1a阴性且HLA-DRB3*01:01阴性的女性,同种免疫及生育严重血小板减少患儿的风险均非常低。

研究设计与样本

  • 系统综述与荟萃分析,检索文献后纳入4项前瞻性研究和8项回顾性研究。
  • 前瞻性研究代表的人群超过150 000。

主要发现

  • 前瞻性研究中严重血小板减少新生儿(血小板计数<50×10⁹/L)64例,其中3例发生颅内出血。
  • 前瞻性研究中64例严重血小板减少新生儿的母亲均为HLA-DRB3*01:01阳性。
  • 回顾性研究中HPA-1a免疫女性分娩的严重血小板减少患儿214例,其中205例出生于HLA-DRB3*01:01阳性母亲。

关键数值与推荐

  • HLA-DRB3*01:01阴性女性同种免疫的OR为0.05(95%CI 0.00-0.60)。
  • HLA-DRB3*01:01阴性女性严重新生儿血小板减少的OR为0.08(95%CI 0.02-0.37)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The most common, severe cases of fetal and neonatal alloimmune thrombocytopenia among whites are caused by antibodies against human platelet antigen 1a (HPA-1a). The aims of this systematic review and meta-analysis are to determine the association between maternal HLA-DRB3*01:01 and: (1) HPA-1a-alloimmunization and (2) neonatal outcome in children born of HPA-1a-immunized women. A systematic literature search identified 4 prospective and 8 retrospective studies. Data were combined across studies to estimate pooled odds ratios (ORs) and the associated 95% confidence intervals (CIs). The population represented by the prospective studies was more than 150 000. In the prospective studies, there were 64 severely thrombocytopenic newborns (platelet count <50 × 109/L) of whom 3 had intracranial hemorrhage. The mothers of all 64 children were HLA-DRB3*01:01+. The number of severely thrombocytopenic children born of HPA-1a-alloimmunized women in the retrospective studies was 214; 205 of whom were born of HLA-DRB3*01:01+ women. For HLA-DRB3*01:01- women, the OR (95% CI) for alloimmunization was 0.05 (0.00-0.60), and for severe neonatal thrombocytopenia 0.08 (0.02-0.37). This meta-analysis demonstrates that the risk of alloimmunization and of having a child with severe thrombocytopenia are both very low for HPA-1a- women who are HLA-DRB3*01:01-.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Kjeldsen-Kragh J, Fergusson DA, Kjaer M, et al. Fetal/neonatal alloimmune thrombocytopenia: a systematic review of impact of HLA-DRB3*01:01 on fetal/neonatal outcome. Blood Adv. 2020. PMID: 32717028. doi:10.1182/bloodadvances.2020002137

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。